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ABSTRACT 
Structural insights into the regulation of JAK3 activity: Evidence from molecular modeling of 
the full human JAK3 protein  
  
 
Jaimie Albach 
Department of Marine Biology 
Texas A&M University 
 
Research Advisor: Dr. Jhenny Galan 
Department of Marine Sciences 
Texas A&M University 
 
 
 JAK3 is a receptor-associated tyrosine kinase that functions a key signal transducer 
within the JAK-STAT cellular signaling pathway to facilitate the production, proliferation, and 
differentiation of various cell types. Mutations to JAK3 have been shown to disrupt 
hematopoietic stem cell signaling, causing abnormalities in immune cell production, linking the 
protein to various immune-deficiency diseases, inflammatory disorders, and cancers. In this 
study we provide key information about JAK3 structure that gives crucial insight into the 
function of the protein at the molecular level, allowing for better understanding of the protein’s 
integral role in cell signaling pathways and immune related disorders. We report two full, 
theoretical 3D structural models of the JAK3 human protein, encompassing all 7 Jak Homology 
(JH) protein domains. The kinase domain (JH1), was obtained from the protein data bank 
(PDBID: 4QPS), while the remaining JH domains were constructed using multi-template 
homology modeling techniques and molecular dynamics simulations. Sequence alignment 
revealed conserved homology properties and JAK2 and TYK2 were used as structural templates 
to model the pseudokinase (JH2) and SH2-FERM (JH3-JH7) domains in JAK3 respectively. 
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Molecular dynamics simulations served to optimize and merge domain models in phases, one 
domain at a time by two different pathways, validating the models at each phase using RMSD 
and energy minimization calculations. The structural and dynamic properties of the protein, 
including residue interactions, domain-domain modulations, and conformational behavior are 
quantified. This study is an important step in better understanding JAK3 structure-function 
mechanisms and molecular interactions and may aid in discovery of novel inhibitors with higher 
JAK3 selectivity through structure-based drug design.  
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ACRONYMS 
 
AMKL Acute Mega-karyoblastic Leukemia 
ATLL  Adult T-cell Leukemia/Lymphoma 
BLAST Basic Local Alignment Search Tool 
EMBL-EBI European Molecular Biology Laboratory- European Bioinformatics Institute 
EMBOSS European Molecular Biology Open Software Suite 
FAK  Focal Adhesion Kinase 
HSC  Hematopoietic Stem Cells 
IL  Interleukin  
JAK  Janus Kinase or Just Another Kinase  
MD  Molecular Dynamics simulations 
MSA  Multiple Sequence Alignment 
NAMD Nanoscale Molecular Dynamics program 
NCBI  National Center for Biotechnology Institute  
NK  Natural Killer cell 
NPT  Constant number molecules/atoms (N), constant pressure (P), and constant  
  temperature (T) ensemble; Isothermal-isobaric ensemble 
NVT  Constant number molecules/atoms (N), constant volume (V), and constant  
  temperature (T) ensemble, canonical ensemble 
PDB  Protein Data Bank 
PDBID Protein Data Bank Identification number  
PW  Pairwise sequence alignment 
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RMSD  Root-Mean Square Deviation  
SCID  Severe Combined Immunodeficiency Disease 
STAT  Signal Transducer and Activator of Transcription  
T-ALL  T-cell lymphoblastic leukemia  
TAMU Texas A&M University 
TYK  Tyrosine Kinase  
VMD  Visual Molecular Dynamics  
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CHAPTER I 
BACKGROUND INFORMATION 
 
 A protein domain is a characteristic range of amino acid residues with a specific 
sequence, structure, and function that can be found almost identically or very similarly in related 
proteins. Though each of the domains of JAK proteins operates independently with unique 
function, the domains must interact with one another in order to accomplish the overall activity 
of the protein. Amino acids do not only participate in covalent interactions with their directly 
adjacent neighbors and intermolecular interactions with slightly distant neighbors to form local 
secondary structures, but they may also interact with one another on different portions of the 
protein. Domain-domain interactions influence conformation significantly and contribute to the 
overall tertiary structure of a protein. Conformational structure therefore is related to domain-
domain coordination which changes in response to domain activity to carry out a protein’s 
function. Consequently, protein function is directly tied to protein structure.  
 Domain structures (along with the primary amino acid sequences) of nearly all the JAK 
family proteins have been elucidated experimentally, giving key insight into domain-domain 
modulations and molecular interactions that result in the proteins’ functions. However for JAK3, 
only a structural model of the kinase domain (JH1) has been elucidated experimentally 
(Goedken, 2015). In order to fully understand the structure-function interactions of JAK3, a full 
tertiary structural model encompassing the JH1 as well as the JH2, SH2, and FERM domains is 
essential.  
 The main objectives of this study are as follows: 1) To generate models of the tertiary 
structures of the pseudokinase (JH2) domain and SH2-FERM (JH3-JH7) using multi-template 
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homology modeling and molecular dynamics (MD) simulations. 2) To generate the full model 
tertiary structures of the JAK3 human protein by combining all protein domains: Kinase (JH1), 
Pseudokinase (JH2), SH2 (JH3-4), and FERM (JH5-7) in a stepwise fashion using MD 
simulations. 3) To validate models and quantify domain-domain interactions by examining key 
residue interactions, such as hydrogen-bonding and salt bridging, among residues at inter-domain 
interfaces. Model structure validation is accomplished at each phase with RMSD and energy 
minimization calculations, various pathways of merging domain structures to explore the 
conformational space, and the identification of functionally significant residues present in our 
models.  
 Knowledge of JAK3 structure provides greater insight into JAK3 function at the 
molecular level furthering understanding of the protein’s role in hematopoietic stem cell 
signaling within the JAK-STAT pathway and the protein’s link to various immune deficiency 
diseases, inflammatory disorders, and cancers.  
JAK Structure 
 Proteins within the same family have similar homology, or high similarity among protein 
sequence, structure, and overall function. There four members of the Janus Kinase or Just 
Another Kinase (JAK) protein family: JAK1, JAK2, JAK3, and Tyrosine Kinase 2 (TYK2) 
(Rane & Reddy, 2000). All four JAK proteins have seven characteristic protein domains termed 
JH1- JH7 or Janus Homology domains (JH) (Figure. 1).  
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Figure 1. JH7-JH1 domains of JAK family proteins. Relative domain ranges of JAK3 found 
using NCBI (National Center for Biotechnology Institute) Protein BLAST (Basic Local 
Alignment Search Tool) (Altschul, 1990).  
 The JH domains of JAKS are categorized into four protein domains: FERM, SH2, the 
Pseudokinase, and the Kinase (Wu & Sun, 2011). The amino acid sequence in JAKs begins with 
JH7 and continues in descending order to JH1. Beginning with the amino N-terminus, JH7, JH6, 
and JH5 comprise the three-lobed FERM domain, thought to be the receptor binding region of 
the protein (Giordanetto & Kroemer, 2002). Following FERM, JH4 and JH3 make up the Src 
homology 2 (SH2) domain, which functions in facilitating phosphorylation of other proteins by 
attracting and binding kinase domain containing proteins (Wu & Sun, 2011). A small segment of 
amino acids follows the SH2 domain linking it to the JH2 domain, or pseudo-kinase domain, 
followed by an additional domain linker region connecting the JH2 to the JH1.  The JAK 
terminates with JH1, the catalytically active kinase domain, which contains key tyrosine residues 
needed for JAK phosphorylation (Rane & Reddy, 2000). Short sequences of residues cap the 
JAK protein at the amino (N-terminus) and carboxyl (C-terminus) ends of the protein. 
The JAK-STAT Pathway 
 The main function of the JAK proteins is to mediate the proliferation and differentiation 
of different cell types. This is achieved by serving as signal transducers during cellular 
communication in the cascade of interactions that occur within various signaling pathways 
(Shuai & Liu, 2003). One of the most important roles of the Janus Kinases is their implication in 
the JAK-STAT (Janus Kinase-Signal Transducer and Activator of Transcription) signaling 
pathway (Figure. 2).  
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Figure 2. JAK-STAT (Janus Kinase- Signal Transducer and Activator of Transcription) 
signaling pathway.  
 As kinase proteins, the main activity of the JAKs within this pathway is phosphorylation, 
in which the JAK transfers a phosphate group from ATP or another energy-rich molecule to a 
separate protein substrate, subsequently causing activation of the phosphorylated protein. To 
activate itself, the JAK may also undergo auto-phosphorylation, where inter-residue transfer of a 
phosphate group occurs within the protein (Chrencik, & et. al, 2010). In the case of tyrosine 
kinases, such as the JAKs, the phosphate group is transferred to specific tyrosine residues, 
located in the kinase domain.  
 The JAK-STAT pathway is initiated with the binding of signaling molecules to 
extracellular portions of receptors on the cell surface (Wu & Sun, 2011). Signaling molecules, 
such as cytokines, interferons, interleukins, or hormones, are released into the extracellular space 
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by other cells to communicate cellular production needs. Since many of the various type I and II 
cytokine receptors that the JAKs interact with do not possess enzymatic kinase activity of their 
own, receptors must rely on JAKs to initiate the signal transduction cascade (Giordanetto & 
Kroemer, 2002). Upon receptor binding to the extracellular portion of the receptor, the 
intracellular receptor-associated JAK binds to the cytoplasmic tail of receptor (Wu & Sun, 2011). 
JAK-receptor binding induces JAK autophosphorylation and subsequent JAK activation. Binding 
of a STAT (Signal Transducer and Activator of Transcription) protein to the activated JAK 
ensues and JAK protein phosphorylation and activation of the STAT protein occurs (Wu & Sun, 
2011).The activated STAT then continues the transduction of the cellular signal by dimerizing 
and entering the nucleus of the cell. Within the nucleus, the STAT binds to promoter regions on 
the DNA, promoting transcription of certain genes for the proliferation, maturation, and 
differentiation of cells (Giordanetto & Kroemer, 2002). 
Hematopoietic Stem Cells and Signaling 
 The JAK-STAT pathway is used by a wide variety of cytokine signaling including 
granulocyte colony-stimulating factors, thrombopoietin, interferons, erythropoietin, and 
interleukins (IL) (Boggon & et. al., 2005). The different JAKs interact with different receptors 
within the pathway and therefore mediate an assortment of cellular processes. JAK1, JAK2, and 
TYK2 are expressed ubiquitously in different cell types, while JAK3 is predominately expressed 
in and mediates the development of hematopoietic stem cells (HSCs) (Chrencik & et. al, 2010). 
HSCs differentiate to form the different blood and immune cells within the body. Therefore 
properly functioning JAK3 protein is crucial for the proper development of these cells and the 
upkeep of a healthy immune system. (Hematopoietic Stem Cells, 2011). When we are well, the 
body has a relatively stable amount of immune cells and red and white blood cell production is 
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regulated with great precision. However, during infection, levels of HSCs fluctuate, and their 
self-renewal and maturation is controlled with interleukins and other signaling growth factors.  
 Interleukin 2 (IL-2) is the principal growth factor in regulating T-lymphocyte 
proliferation as well as the magnitude and duration of T-cell immune response following antigen 
encounter (Zhu & et. al., 1997). One of the most well-known interactions of JAK3 within the 
JAK-STAT pathway is the protein’s association with the interleukin-2 (IL-2) cytokine receptor 
(Zhu & et. al., 1997). Antigen recognition stimulates release of IL-2 growth factor cytokines, 
which interact with the IL-2 receptors on immune cell surfaces to signal for the increased 
production of T-cells. Receptor binding initiates intracellular JAK3 binding to the cytoplasmic 
tail of the common gamma chain (c) of the IL-2 receptors and subsequent signal transduction 
ensues resulting in increased immune cell production. 
  If JAK3 structure is mutated and function becomes aberrant, HSC signaling within the 
JAK-STAT pathway will become disfunctional and abnormal HSCs will be produced. JAK3’s 
interactions within the JAK-STAT pathway therefore make it an important component for the 
proliferation, differentiation, and apoptosis of HSCs and link the protein to a number of immune-
mediated processes.  
Abrogating and Activating Mutations 
 A number of mutations have been identified in JAK3 that have been directly linked to 
various immune deficiency diseases, inflammatory diseases, cancers, leukemias, and 
myeloproliferative disorders. Figure 3 depicts the locations of various mutations for severe 
combined immunodeficiency (SCID) and acute megakaryoblastic leukemia (AMKL) in JAK3. 
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Figure 3. Mutations found in SCID (black), AMKL (red), and both diseases (orange) (Shi, & 
Amin,2007).  
 Patients experiencing various immune deficiency syndromes, characterized by 
insufficient or abnormal immune and blood cell circulation within the body, displayed mutated 
JAK3 with impaired function. One of the most studied of these immune deficiency diseases is 
the autosomal recessive form of Severe Combined Immunodeficiency Disease (SCID) (Vihinen, 
et. al., 2000). If there is an inhibiting mutation in JAK3, abrogating its activity, like is seen in 
SCID, the signals sent by cells calling for the increased production of immune cells to fight off 
infection will only get so far within the JAK-STAT pathway before they are impeded. In SCID, 
decreased JAK-STAT functionality results in the production of abnormal B cells and a decreased 
production of T-cells and NK cells necessary for cell-mediated immunity (Vihinen, et. al., 2000). 
This therefore leads to an increase in infections that characterize SCID and many of the immune 
deficiency diseases as seen in patients with JAK3 abrogating mutations.  
 One study analyzing SCID patient-derived and artificial mutations within the FERM 
domain of JAK3, showed that mutations within this domain impaired kinase-receptor interaction, 
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abrogated catalytic activity, and blocked ATP binding (Zhou et. al. 2001). Coimmuno-
precipitation experiments in the same study utilizing JAK3 wild-type and mutant FERM and 
kinase domains showed that though both types associated, only wild-type FERM domain 
increased kinase activity (Zhou et. al. 2001). These studies suggest mutations in domains other 
than the catalytically active kinase domain, especially the FERM domain, may affect the overall 
function of the protein via domain-domain modulation.   
 Activating mutations within JAK3, like we see in AMKL, acute T-cell lymphoblastic 
leukemia (T-ALL), and other myeloproliferative disorders, deregulate the activity of the protein, 
and more immune or blood cells than necessary are produced. Additionally, many of these 
extraneous cells are improperly produced and without function, and may accumulate in the body 
causing problems that characterize these diseases. Patients with adult T-cell leukemia/lymphoma 
(ATLL), were shown to have mutations in the FERM domain of JAK3 which caused increased 
IL-2 signaling phosphorylation of STAT5A and gain of function in the kinase domain of JAK3 
(Elliott, et. al. 2011). By comparing the JAK3 FERM domain to homologous FAK protein 
domain, this study also suggested FERM intramolecular contact with the kinase domain.  
 Much evidence suggests a link between JAK3 and many immune mediated diseases, yet 
the structural mechanisms behind the interactions, especially at the molecular level, are poorly 
understood. Though much is known about the protein’s function within cellular signaling 
pathways, comprehensive information regarding the mechanisms and interactions at the 
molecular level remain inadequate since there is a lack of structural data concerning JAK3. It is 
known that the kinase domain of JAK3 is responsible for the catalytic activity of the protein. 
However, as suggested by mutagenesis studies, other domains, specifically the FERM domain, 
may interact and modulate the kinase domain function by regulating catalytic activity (Boggon, 
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2005). A full model encompassing all JAK3 domains will provide greater insight into the 
different domain functions, domain-domain modulations, and overall structure-function 
interactions of the protein.  
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CHAPTER II 
METHODS 
 
 The structure of the kinase domain, JH1, of JAK3 was previously elucidated (Goedken, 
2014). Methodology to predict the remaining FERM (JH7-JH5), SH2 (JH3-JH4), and 
pseudokinase (JH2) domains was employed using multi-template homology modeling and 
molecular dynamics simulations. JH2 and SH2-FERM domains were modeled separately, each 
utilizing a template structure from a JAK protein with highly conserved sequence homology to 
JAK3. Domain models were optimized and merged in phases, one domain at a time, using 
molecular dynamics simulations to produce two full models of JAK3, encompassing all domains. 
Validation of models was accomplished with root-mean square deviation (RMSD) calculations, 
energy minimization calculations, and identifying key residues important to functionality in our 
models and verifying their interactions.   
Protein structure prediction: Homology Modeling  
 Protein structure may be predicted by various methods. Classically, protein structure is 
elucidated experimentally via x-ray crystallography or NMR spectroscopy. Though x-ray 
crystallography produces a higher resolution model of protein structure, it also requires the 
protein to be crystallized. Purification of a protein sample and subsequent crystallization is 
difficult for some larger protein families. The protein’s crystalline structure may also vary from 
its solution structure. This is especially true for proteins that are water-soluble by removing a 
source of important intermolecular interactions. Further, crystallization only gives a snapshot of 
the protein, when in reality a protein is actually very dynamic and frequently undergoing 
conformational changes. NMR methodology of protein structure prediction analyzes the protein 
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in solution, mitigating many of the above-mentioned issues associated with crystallization. 
Structural data obtained from NMR frequently supplements theoretical modeling of a protein 
structure by providing additional information regarding residue-residue interactions. However, 
obtaining NMR structural information for protein is limited by size. Therefore, in this study 
computational theoretical modeling of protein structure was utilized to give a more 
comprehensive and dynamic picture of protein structure for JAK3, a relative large protein with 
1124 residues. 
 The three-dimensional structure of JAK3, a relatively large protein (1124 residues), was 
generated using computational multi-template homology modeling techniques and MD 
simulations, to produce a tertiary model comprising all domains (JH1-7). Since the primary 
amino acid sequence of a protein is directly related to its structure and therefore function, the 
rationale behind homology modeling is that proteins with highly conserved sequences also have 
conserved structure and overall function (Karadaghi, 2015). Therefore, this method utilizes 
proteins with known structures and conserved sequence homology with respect to a target 
protein, as templates to model the unknown structure of a target protein. Separate models for the 
different domains were generated using different templates and then combined using two 
different pathways. Molecular dynamics simulations were used to generate multiple probable 
model structures at each phase. 
Generation of JAK3 domain models 
 For ease of modeling, due to the large size of the JAK3 protein and in order to better 
conserve homology among domains, models of the JH2 (pseudokinase domain), and the JH3-
JH7 regions (SH2-FERM domain), were constructed separately.  
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Homology among JAKs: Multiple Sequence Alignments  
 In general, proteins within the same family are grouped together due to highly conserved 
homology. Sequence homology within the JAK family was confirmed in order to determine if 
the different JAK family proteins would be suitable templates for JAK3 modeling. Sequences of 
JAK1, JAK2, JAK3, and TYK2 from various species were obtained from the NCBI Gene 
Database using BLAST (Basic Local Alignment Search Tool) (Altschul, 1990) (Table 1). 
Table 1. JAK family protein sequences obtained from NCBI BLAST. Accession version (gi) ID 
number given for each sequence used on NCBI website.  
Jak 1 Jak2  Jak3 Tyk2 Band 4.1 proteins  
Homo sapiens 
Homo sapiens  
ID: P23458.2 
Homo sapiens  
ID: O60674.2 
Homo sapiens 
ID: P52333.2 
Homo sapiens  
ID: AAH14243.1 
Ezrin  
ID: NP_003370.2 
Pan troglodytes 
ID: JAA44554.1 
Pan troglodytes  
ID: JAA41169.1 
Cyprinus carpio 
ID: AAF24169.1 
Pan troglodytes 
ID: JAA43378.1 
Radixin 
ID: AAA36541.1 
Danio rerio 
ID: AAH47165.1 
Mus musculus  
ID: EDL41674.1 
Mus musculus  
ID: Q62137.2 
Mus musculus 
ID: AAY21060.1 
Moesin  
ID: NP_002435.1 
Rattus norvegicus 
ID: EDL97824.1 
Siniperca chuatsi 
ID: ACU12481.1 
Rattus norvegicus 
ID: NP_036987.2 
Sus scrofa 
ID: CAG15148.1 
B4.1 
ID: P11171.4 
Bos taurus  
ID: DAA31301.1 
Tetraselmis 
ID: JAC84248.1 
Gallus gallus 
ID: NP_990327.1 
Bos taurus 
ID: DAA27926.1 
 
 Xenopus laevis 
ID: 
NP_001085288.3 
 Xenopus laevis 
ID: 
NP_001085663.1 
 
 
 In order to determine homology among the sequences collected, the sequences were 
aligned in pairwise sequence alignments (PW) and multiple sequence alignments (MSA) using 
NCBI BLAST, CLUSTAL OMEGA (Sievers, et. al, 2011), and EMBOSS Needle (Rice, et. al, 
2000) online analysis tools. In a sequence alignment, an algorithm is used to match up similar 
amino acid residues among two or more protein sequences. Sequences may be shifted forward or 
backward from one another or broken up into different sections, creating gaps within the 
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sequence, with the ultimate goal of aligning as many identical or similar residues among the 
sequences as possible. The alignment produced depicts the residues and gaps conserved among 
the sequences. Similarity values are also generated, translating those conserved residue 
properties into quantitative percentages that reveal the overall homology among the protein 
sequences.     
 The full sequences of JAK1, JAK2, JAK3, and TYK2 from the species listed in Table 1 
(excluding Band 4.1 proteins) were aligned in an MSA using the CLUSTAL OMEGA tool on 
the EMBL-EBI (European Molecular Biology Laboratory-European Bioinformatics Institute) 
website (Sievers, 2011). The CLUSTAL OMEGA program operates using the Hhalign algorithm 
to identify and maintain conserved residue properties (Soding, 2005). By comparing the entire 
sequence of each protein, encompassing all domains, the results of the full MSA were used to 
determine which JAK protein was most similar to JAK3 overall, among all domains.  
 In a separate MSA, the homology of the JH2 domain among the JAK proteins was 
investigated by aligning only the JH2 portions of the sequences of JAK1, JAK2, JAK3, and 
TYK2 from Table 1. The purpose of aligning just the JH2 portions was to give a more precise 
alignment of conserved residues among the proteins with respect to only the JH2 domains. 
Similarity value results from the JH2 domain-specific MSA revealed which JAK protein had the 
most homologous JH2 domain to the JH2 domain of JAK3.   
 Similarly, one more MSA was created aligning only the SH2-FERM domains of JAK 
family proteins (Table 1) to ascertain the JAK with the most similar SH2-FERM domain to that 
of JAK3. This MSA included the Band 4.1 proteins listed in Table 1 since the FERM domain is 
structurally very similar to the domains associated with this protein (Girault, et. al., 1999).  
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Identification of Structural Templates 
 The different MSAs produced gave varying similarity values revealing which JAK 
proteins would be most suitable for use as templates for JAK3 domain models. The next step was 
to search the RCSB protein data bank (PDB) for available domain structures of the most 
homologous JAKs (Berman, et. al., 2000). Structural templates for each of the JH2 and SH2-
FERM domains were then chosen based on highest MSA similarity values to the respective 
JAK3 domain, availability on the PDB, and highest resolution model.  
Pairwise Alignments 
 With templates chosen, a PW was completed for each the JH2 and SH2-FERM domains 
aligning the JAK template with the respective JAK3 domain.  Since residue alignments shift 
depending on the sequences involved, the PW was completed in order to obtain one more 
possible alignment of sequences, with the possibility of creating an alignment with increased 
conserved residue properties. The EMBOSS (European Molecular Biology Open Software Suite) 
Needle program on the EMBL-EBI website was used to perform the pairwise alignment (Rice & 
et. al, 2000). The Needle program utilizes the Needleman-Wunsch algorithm to perform a global 
alignment, which, when compared to local alignment programs, allows for more query cover, 
aligning the most residues without truncating residues from the ends of the sequences. 
Generation of domain models 
 Homology models of the JH2 domain and SH2-FERM domain were generated using the 
MODELLER 9.17 program (Sali, A. and Bundell, T. L., 1993). The program essentially takes 
the residues from a template sequence with a structure and substitutes the residues from a target 
sequence (JAK3) into the template structure, thereby creating a rough structural model of the 
target sequence. In order to do this, the program requires an alignment of the template and target 
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sequences of the same length. During the MSA and PW alignments, sequences were shifted to 
increase conservation of residues, creating gaps in the sequences in the process. Therefore the 
template sequence in the full MSA, domain-specific MSA, and PW sequence alignments for 
each domain, had to be modified accordingly to diminish these gaps, ensuring proper alignment 
of conserved residues and identical sequence length. Residues were deleted from the template 
when a gap was aligned in the corresponding location on the target sequence. Gaps appearing on 
the template sequence were inserted with aligned residues from the target sequence. The 
biopolymer function on the SYBYL X 2.0 program (Certara Inc.) was then used to update the 
PDB structure file of the template to reflect the modifications made to its sequence. 
 MODELLER 9.17 was used to create 5 rough structural models of each the JH2 and 
SH2-FERM domains of JAK3 for each the full MSA, domain-specific MSA, and PW 
alignments. For each domain, the theoretical models produced from each alignment were 
superimposed with respect to their template structure and root-mean square deviation (RMSD) 
calculations were performed using visual molecular dynamics visualization program (VMD) 
(Humphrey,W.Dalke, A., and Schulten, K, 1996). Results from RMSD calculations revealed 
which structural models produced, deviated the least from its template. The theoretical models 
with the least structural deviations were chosen as the initial model for each domain and were 
subsequently optimized.    
Molecular dynamics simulations 
 JAK3 domain models were optimized with all-atom molecular dynamics (MD) 
simulations in solvent environment (Figure 4) using the Nanoscale Molecular Dynamics 
(NAMD) Program (Phillips, 2005). A summary of simulation details is shown in Table 2.  
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Figure 4. Depiction of the JH2 domain model solvated with water box padding for sample 
simulation setup.  
  
Table 2. MD simulation details for JH2 and SH2-FERM domains individually and each 
subsequent merge of domains. 
 Number 
of total 
atoms 
Number 
of solvent 
molecules 
Cell dimensions 
(L x W x H) 
(Angstroms) 
Simulation 
times (ns) 
JH1 36420 10692 70.3 x 70.3 x 70.3 10 
JH2 55705 17119 77.7 x 77.7 x 77.7 10 
SH2-FERM 79643 24068 91.3 x 91.3 x 91.3 12 
(JH2)-(SH2-FERM) merge 262869 83695 136 x 136 x 136 17 
(JH1)-(JH2) merge 174,700 55336 124 x 124 x 124 10 
(JH1-JH2)-(SH2-FERM) merge 253896 79255 150 x 150 x 150 underway 
(JH1)-(JH2-SH2-FERM) merge 253896 79255 150 x 150 x 150 underway 
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 All model systems were initially minimized to remove bad interactions using conjugate 
gradient minimization algorithm within NAMD. The solvated systems were initially equilibrated 
at 0.5 fs timestep, 300 K and 1 atm pressure in the NPT ensemble using the Nose-Hoover 
Langevin piston pressure control. The Langevin piston Nose-Hoover method in NAMD is a 
combination of the Nose-Hoover constant pressure method (Martyna & et. al., 1997) with piston 
fluctuation control implemented using Langevin dynamics (Feller & et. al., 1995). After 
equilibration, production run was carried out using Langevin dynamics (Kubo et. al., 1991). 
Total simulation times for each system are also shown in Table 2.  All structural analyses were 
based on the total production trajectory with a collection interval of 1.0 ps. The Charmm 36 
forcefield (Best, R.B., 2012) was used for all protein simulations. 
 For each system, structures obtained from the NVT MD simulation were clustered based 
on their RMSD values relative to the beginning structure as reference. Energy minimization 
calculations were performed on each representative structure from each cluster in order to 
determine the lowest energy model to be used for each domain. Chosen optimized models of the 
individual domains were then used to assemble a full structural model of JAK3 using additional 
MD simulations. Assembly of the full model was accomplished in phases, combining one 
domain at a time in different orders for a total of two pathways generating two full probable 
models. The rationale behind merging the domains in different orders was to allow the domains 
to interact with one another in multiple ways, allowing an improved search of the conformational 
space. 
Structural Analysis 
 For the different models, domain-domain interactions were quantified by calculating 
hydrogen-bonding interactions and salt-bridge interactions for the trajectories. Hydrogen 
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bonding interaction (short- and medium-range) between residues were calculated using 5.0 
angstroms cutoff distance between the donor (D) atom and the acceptor (A) atom and 20
o 
 <ADH 
angle cutoff. Salt bridge interactions were calculated by determining the distance between 
oxygen atoms of acidic residues and nitrogen atoms of basic residues with a cutoff distance of 
3.2 Å.. Domain-domain modulation and interaction was expounded upon by highlighting key 
residues within the protein. Residues were highlighted that are known to have a distinct effect on 
the overall functionality of the protein when mutated along with tyrosine residues at catalytically 
active phosphorylation sites. Inter-domain proximity of these functional residues indicated 
interaction among domains. Quantifying the distance between interacting residues validated 
known domain-domain interactions and new information about domain function and residue 
interaction within the protein among domains.   
Computational Resources 
All molecular dynamics simulations were carried using an Intel x86-64 Linux cluster with 852 
compute nodes at the Texas A&M University High Performance Research Computing Facility 
(College Station, TX). All system setup and data analyses were performed using AMD-based 
workstations. 
  
24 
CHAPTER III 
RESULTS & DISCUSSION 
 
Homology and Template data  
 MSA and PW alignments provided sequence similarity values of the JAK proteins to 
JAK3, used to identify structural domain templates for modeling. Table 3 presents a summary of 
similarity values from each of the three MSAs created, revealing the similarity between human 
JAK1, JAK2, and TYK2 with respect to JAK3.  
 
Table 3. MSA and PW sequence alignment similarity value data. Asterisk (*) designates 
alignment and JAK template protein chosen for each domain.  
Alignment Percent similarity of templates to JAK3 
 JAK1 JAK2 TYK2 
JH2-domain 
specific MSA 
45.52% 57.09%* 45.90% 
SH2-FERM 
specific MSA 
34.21% 39.65% 33.47%* 
Full MSA 42.06% 49.45% 40.82% 
Domain Pairwise N/A 56.9% 31.4% 
  
 Across all sequence alignments, JAK2 had the highest similarity to JAK3. Therefore with 
the highest sequence homology, JAK2 was determined to be the best candidate to be used as the 
template for modeling the JH2 and SH2-FERM domains of JAK3. However, when the RCSB 
protein data bank was searched for JAK2 domain structures, only structures for the JH2 domain 
of JAK2 were available, while SH2-FERM domain structures of the protein were not yet 
accessible. The JAK2 JH2 structure with PDBID: 4FVR was chosen with the highest resolution 
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available at the time (2.0A) (Bandaranayake, 2012). SH2-FERM domain structures for JAK2 
(PDBID: 4Z32) and JAK1 (PDBID: 5IXI) did not become available until 6/22/2016 and 
5/18/2016 respectively (McNally, 2016; Ferrao, 2016). Therefore, of the JAK proteins, the only 
available structure of the SH2-FERM domain at the time the domain models were generated was 
from the TYK2 protein (PDBID: 4PO6) (Wallweber, 2014). The TYK2 structure of SH2-FERM 
also had better resolution (1.99A) than this domain structure for JAK1 (2.57A) and JAK2 
(3.04A).  Therefore the SH2-FERM domain structure of TYK2 was chosen as the template for 
modeling the corresponding domain in JAK3.  
 The structure of the JH1 domain, already previously elucidated, was chosen for use in our 
model from the list of available structures on the PDB based on highest resolution of available 
structures at the time of the experiment. At the time, PDBID: 3LXL and PDBID: 4QPS were the 
highest resolution structures of JH1 available of 1.74A and 1.8A respectively. The 3LXL 
structure was not chosen as the representative structure of JH1 to be used in our model since it 
was a complex of JAK1, TYK2, and other compounds. Therefore, the 4QPS structure was 
chosen for the JH1 domain of JAK3 to use in our model (Goedken, 2015). A summary of 
structural domain templates chosen for use in our model is depicted Table 4.  
 
Table 4. JAK proteins chosen as structural templates for the domains of JAK3 obtained from the 
RCSB protein data bank.  
Domain PDBID JAK protein Resolution  Date Released  Reference 
JH1 4QPS JAK3 1.8 A 01/14/15 Goedken, 2015 
JH2 4FVR JAK2 2.0 A 07/25/12 Bandaranayake, 2012 
SH2-FERM 4PO6 TYK2 1.99 A 04/02/14 Wallweber, 2014 
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RMSD and Energy minimization validation 
 Following the identification of structural templates, Modeller 9.17 was used to create 5 
rough structural models of each of the domains, one of which was chosen for each domain based 
on lowest RMSD values to be used for further optimization. Backbone RMS deviation of chosen 
SH2-FERM model from TYK2 template (PDBID: 4PO6) was 4.94 angstroms. Backbone RMS 
deviation of chosen JH2 model from JAK2 template (PDBID: 4FVR) was 2.06 angstroms.  
 Models selected for each domain were minimized and optimized using MD simulation in 
solvent environment and analyzed for structural deviation with RMSD trajectory calculations. 
Figures 5 & 6 depict RMSD values for the simulations of the JH2 domain model and SH2-
FERM domain model respectively using the first frame as the reference structure. 
 
 
Figure 5. RMSD values of optimized JH2 domain model with respect to original template 
structure over the course of the MD simulation. Each frame represents a snapshot of the structure 
of the JH2 model where increasing frame number corresponds to increasing amount of time the 
protein model was run at 300K (NVT). RMSD values presented in units of Angstroms (Å). 
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Figure 6. RMSD values of optimized SH2-FERM domain model with respect to original 
template structure over the course of the MD simulation. Each frame represents a snapshot of the 
structure of the SH2-FERM model where increasing frame number corresponds to increasing 
amount of time the protein model was run at 300K (NVT). RMSD values presented in units of 
Angstroms (Å).  
 RMSD trajectory plots show clustering of structures at certain values. Structures were 
selected from each RMSD value cluster underwent additional energy minimization. Energy 
minimization calculations (Table 5) were performed on each structure to determine the lowest 
energy domain model.  
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Table 5. Results from energy minimization calculations for each the JH2 and SH2-FERM 
models. Energies presented as relative energies with respect to lowest energy model.  
Frame   
(JH2 structure) 
Relative energies 
(kcal/mol) 
 Frame (SH2-FERM 
structure) 
Relative Energies 
(kcal/mol) 
              625 107.0241 1000 382.0698 
1380 199.1805 2000 491.3359 
2050 399.7004 2900 348.9356 
3600 157.1997 3500 97.0701 
4800 210.4949 4400 323.9464 
6200 184.994 5000 156.2752 
7100 188.2698 6500 40.5313 
8500 298.2372 7300 63.6948 
10000 359.419 8300 342.1475 
13500 35.8906 10500 147.2586 
16800 179.0692 11600 24.4063 
17500 167.8347 13000 0 
18500 0 13700 61.9413 
19300 140.2411 15000 192.0517 
19900 137.7126 15900 253.749 
  17500 182.1309 
 
 Lowest energy domain models selected were used subsequently in building the merged 
models, JH2-JH1 model and FERM-SH2-JH2 model. Independent MD simulations were carried 
out for each of the merged structures. For each model, the trajectories were clustered based on 
their RMSD values relative to a reference structure. RMSD data in Figure 7 (JH1-JH2 merge) 
and Figure 8 (JH2-SH2-FERM merge). A representative structure from each cluster was 
subjected to energy minimization to compare the models obtained. Energy minimization results 
in Table 6 for each merged model. 
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Figure 7. RMSD values of the optimized model of the JH1 domain merged with the JH2 domain 
over the course of the MD simulation with respect to the beginning structure of the model before 
MD simulation ensued. Each frame represents a snapshot of the structure of the JH1-JH2 merged  
model where increasing frame number corresponds to increasing amount of time the protein 
model was run at 300K (NVT). RMSD values presented in units of Angstroms (Å). 
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Figure 8. RMSD values of the optimized model of the JH2 domain merged with the SH2-FERM 
domain over the course of the MD simulation with respect to the beginning structure of the 
model before MD simulation ensued. Each frame represents a snapshot of the structure of the 
JH2-SH2-FERM merged  model where increasing frame number corresponds to increasing 
amount of time the protein model was run at 300K (NVT). RMSD values presented in units of 
Angstroms (Å). 
Table 6. Results from energy minimization calculations for each the JH1-JH2 merged model and 
JH2-SH2-FERM merged model. Energies presented as relative energies with respect to lowest 
energy model for each simulation.  
Frame (JH1-JH2 
merge structure) 
Relative energies 
(kcal/mol) 
 Frame (JH2-SH2-FERM 
merge structure) 
Relative Energies 
(kcal/mol) 
1398 114.0333 15473 279.4626 
1807 18.2943 13710 584.1231 
2826 230.0102 19104 377.4947 
3613 128.2497 17215 597.6278 
4413 147.097 21287 211.9521 
5232 61.3441 21380 0 
6156 71.5865 24124 244.8753 
6809 124.9345 32204 36.5425 
7368 74.6408 33826 272.0179 
7570 181.1973 34531 238.3733 
7629 58.4832 35436 359.3718 
7980 0 37205 396.6667 
8547 70.1507 38588 284.8 
9670 124.2963 40548 545.3102 
  42205 471.5956 
  43120 572.7942 
  46083 427.7317 
  44371 362.0231 
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Generation of Full Structural Model 
 The assembly of the full model of JAK3 was accomplished in several phases. Two 
pathways were utilized to generate the full model (Figure 9). 
 
Figure 9. Two visual pathways depict the manner in which domains of JAK3 were merged into 
two full models. Domain colors depicted as follows: JH1 kinase domain (yellow), JH2 
pseudokianse domain (Light blue), SH2 domain (purple), and FERM domain with lobes A, B, 
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and C (red, green, blue respectively). The structure for the JH1 domain depicted was obtained 
from the PDB (PDBID: 4QPS) and further optimized with MD simulation for use in our full 
model. The JH2 and FERM domains were generated using methodology described.  
  
  In the first path, the JH1 domain (PDBID: 4QPS) was merged with the JH2 domain by 
orienting the end sequence of the JH2 domain with the start of the JH1 domain. The system was 
then solvated and subjected to similar MD simulation procedure described in methodology but 
with longer simulation times (Table 2). RMSD trajectories from the simulations were clustered 
and representative structures (without water molecules) were minimized similar to the methods 
above. The selected structure/s were merged with the SH2-FERM domain model followed by 
similar optimization procedures described.  
 In the second path, the SH2-FERM domain was merged with the JH2 domain in a 
separate series of MD simulations (Table 2). Further, the JH1 domain was merged with the JH2-
SH2-FERM model (Table 2). All simulations parameters, clustering methods, and selection of 
most probable structure/s were the same for the two paths. This resulted in two full models of 
JAK3 comprising all domains depicted in Figure 9.  
Structural Analyses of the Models  
FERM-SH2-JH2 model.  
 The FERM-SH2 model (Figure 10) obtained resembles the typical structural motifs, 
alpha helical structures and β-strand structures of a FERM domain consisting of three major 
lobes, A, B, and C (Giordanetto & Kroemer, 2002; Hamada, et. al., 2000). In the model 
structures, Y100 is shown in the interior core of the FERM domain. Y100C mutation has been 
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correlated with SCID, which can be correlated to structural destabilization of the FERM lobes 
with the mutation. SH2 (or SH2-like domain) consists of β-strands and an α-helical structure. 
 
Figure 10. FERM-SH2 model with FERM lobes A (red), B (green), and C (blue), and SH2 
(purple) depicting key secondary structures and key residues are highlighted. 
  
 The organization of the FERM-SH2 domains is stabilized by both short-range and long-
range salt-bridge and hydrogen bonding interactions (summarized in Table 7). Residues depicted 
in FERM-SH2-JH2 model in Figure 11.  
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Table 7. Summary table of hydrogen-bonding and salt bridge interactions at domain interfaces in 
JAK3 model. 
Domain 
Interface 
Interaction 
FERM-
SH2 
Hydrogen Bonding  Salt Bridges  
Residues Residues Average distance 
(Angstroms) 
Distance Range  
(Angstroms) 
H116---H492 R121---D383 D294---R490 6.37 3.26 to 12.52 
C115---R490 R117---R490 D276---R490 8.54  3.35 to 14.23 
SH2-JH2 D383---E547 T381---E547 D383---R549 4.43  3.30 to 6.47 
Y425---R657 
FERM-
JH2 
 R121---E522 9.09 3.30 to 6.47 
R121---E547 6.46 3.84 to 9.40 
JH2-JH1 S779---P814 D784---E819  E786---R899 4.19 3.09 to 10.49 
 S779---I816 D776---Y886    
  
 Hydrogen bond interactions and electrostatic interactions were analyzed between the two 
domains. The key hydrogen-bond and salt-bridge interactions include H492 (SH2) and H116 
(FERM), R121 (FERM) and D383 (SH2), C115 (FERM) and R490 backbone (SH2), R117 
(FERM) and R490 backbone (SH2). The hydrogen-bonding interactions showed occupancies 
>60 % throughout the entire simulation. A prominent long-range electrostatic interaction is 
shown between D276 (FERM) and R490 (SH2), and D294 (FERM) and R490 (SH2), with an 
average salt-bridge distance of 8.54Å and 6.37 Å throughout the simulation respectively.  
Mutation of these residues will likely cause disruption in the interaction network. The hydrogen-
bonding and salt-bridge analyses were carried out for every 5000 frames of the trajectories 
collected. 
 The interface between the SH2 domain and the JH2 domain is characterized by many 
hydrogen-bonding and salt-bridge interactions summarized in Table 7 and depicted in Figure 11.  
35 
 
Figure 11. Key residue interactions highlighted on JH2, SH2, and FERM domains.  
 
 Key hydrogen-bonding interactions occur between D383 (SH2) and E547 (JH2) as well 
as between T381 (SH2) and E547 (JH2), which exhibited ~80% hydrogen-bonding occupancy 
through the simulation. A close interaction was also observed between Y425 (SH2) and R657 
(JH2) but is only present ~ 10% of the time. The JH2 and FERM-SH2 domains also showed salt-
bridge interactions between D383 (SH2) and R549 (JH2), D522 (JH2) and R121 (FERM) , E547 
(JH2) and R121 (FERM), with average distances of 4.43, 9.09, 6.46 angstroms, respectively. 
JH1-JH2 model 
 As shown in Figure 12, there are a few key residues that line the JH2-JH1 interface. A 
summary of hydrogen-bonding and salt bridge interactions is recorded in Table 7. 
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Figure 12. Key residue interaction between residues on JH2 and JH1 domains highlighted. 
 
 Based on analysis of the trajectories, stable hydrogen bonding interactions (59.3-70% 
occupancies) were observed between S779 backbone (JH2) and P814 backbone (JH1), D784 
(JH2) and E819 (JH1), I816 (JH1) and S779 (JH2), D776 and Y886. Stable salt-bridge 
interactions are exhibited by E786-R899, which are most likely similar to the case exhibited in 
JAK2 in a previous study (Shan, Y., 2014). In JAK2, mutation of these residues showed an auto-
inhibitory effect.  
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CONCLUSION IV 
 
 Two probable models of the JAK3 protein are reported, though further optimization and 
validation of the models is necessary. The confidence that our model is most probable is 
validated in many ways throughout our methodology. Beginning with template selection, 
templates were chosen based on highest homology to JAK3 using three different alignments of 
sequences in order to ensure most accurate conserved residue properties. Selected template 
structures therefore were already very similar to JAK3 structure, exemplified by relatively low 
RMSD values for each domain after Modeller 9.17 was used to produce rough models. RMSD 
structural validation and lowest energy minimization validation of domain models at each 
subsequent merge phase, supported that models selected at each phase had lowest structural 
deviation and energy. Relatively long simulation times allowed sampling of the conformational 
space and provided various low energy stable model structures. Merging the models using two 
different pathways also provided the possibility of different interactions and orientations of 
domains. Structural deviations between these models must be analyzed further to ensure one 
most probable model for JAK3. Further validation of the models verifying functionally 
significant residues demonstrated inter-domain interactions of JH2 and SH2-FERM along with 
JH1 and JH2. Key residue interactions have also been identified in the models. Mutagenesis 
studies (beyond the scope of this study) on those key residues will be an interesting endeavor to 
see how those affect the structure and function of JAK3. 
Broader Impacts: Inhibitor Potential 
 Due to the observed link between JAK3 and various immune diseases, JAK3 has been 
targeted for the development of selective therapeutic compounds to inhibit JAK3 in patients with 
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activating mutations. The idea behind selective inhibitors is to target the specific biological 
molecule of interest and inactivate only that molecule for a period of time in order to abrogate its 
activity, having less far-reaching side effects than broader treatments such as chemotherapy. 
Depending on the structural specificity of the drug to the target molecule, the inhibitor may 
inhibit other molecules with similar structure causing unwanted side-effects. As of now, the 
design of JAK3 inhibitors developed (Goedken & et. al., 2015; Meyer & et. al., 2010; Jaime-
Figueroa & et. al., 2013) has been limited to targeting just the kinase domain of JAK3. The 
comprehensive model of our protein gives greater insight into the structure-function mechanisms 
of the protein and may aid in developing more selective inhibitors with greater specificity 
through structure-based drug design.  
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